301 related articles for article (PubMed ID: 35748745)
21. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.
Augustyn A; Borromeo M; Wang T; Fujimoto J; Shao C; Dospoy PD; Lee V; Tan C; Sullivan JP; Larsen JE; Girard L; Behrens C; Wistuba II; Xie Y; Cobb MH; Gazdar AF; Johnson JE; Minna JD
Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14788-93. PubMed ID: 25267614
[TBL] [Abstract][Full Text] [Related]
22. Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor.
Kim G; Kim M; Nam EJ; Lee JY; Park E
Am J Surg Pathol; 2024 Mar; 48(3):364-372. PubMed ID: 37981832
[TBL] [Abstract][Full Text] [Related]
23. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.
Szczepanski AP; Zhao Z; Sosnowski T; Goo YA; Bartom ET; Wang L
Genome Med; 2020 Jul; 12(1):63. PubMed ID: 32669118
[TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC).
Ding XL; Su YG; Yu L; Bai ZL; Bai XH; Chen XZ; Yang X; Zhao R; He JX; Wang YY
World J Surg Oncol; 2022 Feb; 20(1):54. PubMed ID: 35220975
[TBL] [Abstract][Full Text] [Related]
25. System analysis identifies distinct and common functional networks governed by transcription factor ASCL1, in glioma and small cell lung cancer.
Donakonda S; Sinha S; Dighe SN; Rao MRS
Mol Biosyst; 2017 Jul; 13(8):1481-1494. PubMed ID: 28742165
[TBL] [Abstract][Full Text] [Related]
26. Comparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer.
Hokari S; Tamura Y; Kaneda A; Katsura A; Morikawa M; Murai F; Ehata S; Tsutsumi S; Ishikawa Y; Aburatani H; Kikuchi T; Miyazono K; Koinuma D
Mol Oncol; 2020 Feb; 14(2):277-293. PubMed ID: 31782890
[TBL] [Abstract][Full Text] [Related]
27. Significance of achaete-scute complex homologue 1 (ASCL1) in pulmonary neuroendocrine carcinomas; RNA sequence analyses using small cell lung cancer cells and Ascl1-induced pulmonary neuroendocrine carcinoma cells.
Kudoh S; Tenjin Y; Kameyama H; Ichimura T; Yamada T; Matsuo A; Kudo N; Sato Y; Ito T
Histochem Cell Biol; 2020 Jun; 153(6):443-456. PubMed ID: 32170367
[TBL] [Abstract][Full Text] [Related]
28. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies.
Ng J; Cai L; Girard L; Prall OWJ; Rajan N; Khoo C; Batrouney A; Byrne DJ; Boyd DK; Kersbergen AJ; Christie M; Minna JD; Burr ML; Sutherland KD
Clin Cancer Res; 2024 May; 30(9):1846-1858. PubMed ID: 38180245
[TBL] [Abstract][Full Text] [Related]
29. MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex.
Llabata P; Torres-Diz M; Gomez A; Tomas-Daza L; Romero OA; Grego-Bessa J; Llinas-Arias P; Valencia A; Esteller M; Javierre BM; Zhang X; Sanchez-Cespedes M
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34493659
[TBL] [Abstract][Full Text] [Related]
30. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
[TBL] [Abstract][Full Text] [Related]
31. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L
Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer.
Wei J; Liu L; Guo Y; Zhang J; Wang X; Dong J; Xing P; Ying J; Yang L; Li J
Thorac Cancer; 2021 Jan; 12(1):40-47. PubMed ID: 33191657
[TBL] [Abstract][Full Text] [Related]
33. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer.
Huang YH; Klingbeil O; He XY; Wu XS; Arun G; Lu B; Somerville TDD; Milazzo JP; Wilkinson JE; Demerdash OE; Spector DL; Egeblad M; Shi J; Vakoc CR
Genes Dev; 2018 Jul; 32(13-14):915-928. PubMed ID: 29945888
[TBL] [Abstract][Full Text] [Related]
34. An integrative transcriptome analysis reveals a functional role for thyroid transcription factor-1 in small cell lung cancer.
Horie M; Miyashita N; Mattsson JSM; Mikami Y; Sandelin M; Brunnström H; Micke P; Nagase T; Saito A
J Pathol; 2018 Oct; 246(2):154-165. PubMed ID: 29876935
[TBL] [Abstract][Full Text] [Related]
35. KDM6A epigenetically regulates subtype plasticity in small cell lung cancer.
Duplaquet L; Li Y; Booker MA; Xie Y; Olsen SN; Patel RA; Hong D; Hatton C; Denize T; Walton E; Laimon YN; Li R; Jiang Y; Bronson RT; Southard J; Li S; Signoretti S; Qiu X; Cejas P; Armstrong SA; Long HW; Tolstorukov MY; Haffner MC; Oser MG
Nat Cell Biol; 2023 Sep; 25(9):1346-1358. PubMed ID: 37591951
[TBL] [Abstract][Full Text] [Related]
36. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
[TBL] [Abstract][Full Text] [Related]
37. ASCL1 regulates the expression of the CHRNA5/A3/B4 lung cancer susceptibility locus.
Improgo MR; Schlichting NA; Cortes RY; Zhao-Shea R; Tapper AR; Gardner PD
Mol Cancer Res; 2010 Feb; 8(2):194-203. PubMed ID: 20124469
[TBL] [Abstract][Full Text] [Related]
38. Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer.
Patel AS; Yoo S; Kong R; Sato T; Sinha A; Karam S; Bao L; Fridrikh M; Emoto K; Nudelman G; Powell CA; Beasley MB; Zhu J; Watanabe H
Sci Adv; 2021 Jan; 7(5):. PubMed ID: 33514539
[TBL] [Abstract][Full Text] [Related]
39. MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.
Ireland AS; Micinski AM; Kastner DW; Guo B; Wait SJ; Spainhower KB; Conley CC; Chen OS; Guthrie MR; Soltero D; Qiao Y; Huang X; Tarapcsák S; Devarakonda S; Chalishazar MD; Gertz J; Moser JC; Marth G; Puri S; Witt BL; Spike BT; Oliver TG
Cancer Cell; 2020 Jul; 38(1):60-78.e12. PubMed ID: 32473656
[TBL] [Abstract][Full Text] [Related]
40. Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers.
Huang F; Ni M; Chalishazar MD; Huffman KE; Kim J; Cai L; Shi X; Cai F; Zacharias LG; Ireland AS; Li K; Gu W; Kaushik AK; Liu X; Gazdar AF; Oliver TG; Minna JD; Hu Z; DeBerardinis RJ
Cell Metab; 2018 Sep; 28(3):369-382.e5. PubMed ID: 30043754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
